ACADIA Pharmaceuticals Inc (MEX:ACAD)
MXN 509 0 (0%) Market Cap: 50.07 Bil Enterprise Value: 41.15 Bil PE Ratio: 83.33 PB Ratio: 4.82 GF Score: 75/100

Q4 2019 ACADIA Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2020 / 10:00PM GMT
Operator

Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals' Fourth Quarter and Full Year 2019 Financial Results Conference Call. My name is Liz, and I will be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to Mark Johnson, Vice President, Investor Relations at ACADIA. Please proceed.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you, Liz. Good afternoon and thank you for joining us on today's call to discuss ACADIA's fourth quarter and full year 2019 financial results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide an overview of our Q4 and full year 2019 financial performance and share our 2020 guidance and priorities. Also joining us today is Michael Yang, our Chief Commercial Officer, who will provide updates on our commercial initiatives; and Dr. Serge Stankovic, our President, who will discuss our pipeline progress. Our Chief Financial Officer, Elena Ridloff, will then discuss our financial results in more detail

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot